Zobrazeno 1 - 10
of 22 540
pro vyhledávání: ''
Autor:
Emily Kessler, Rodrigo Saad-Berreta, Hongwu Zheng, Vikram Deshpande, Krishna S. Tummala, Brandon Nicolay, William Shen, Ramzi Adil, Meng-Ju Wu, Juan Dubrot, Lipika Goyal, Vajira Weeresekara, Amaya Pankaj, Mathias Heikenwalder, Tong Wang, Mirian Fernandez-Vaquero, María García-Beccaria, Ting-Yu Wei, Kira E Olander, Sebastien Ronseaux, Vindhya Vijay, Qibiao Wu, Yuanli Zhen, Christine Hudson, Nabeel Bardeesy, Lei Shi, Rahul M. Kohli, Meiqi Luo, Yi Sun, Russell W. Jenkins, Robert T. Manguso, Cristina R. Ferrone, Joshua Merritt
Publikováno v:
Cancer Discovery. 12:812-835
Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple α-ketoglutarate–dependent enzymes, altering epigenetics and metabolism. Here, by developing mIDH1
Autor:
Robert Yarchoan, Kathryn Lurain, Denise Whitby, Ramya Ramaswami, Mark N. Polizzotto, Anaida Widell, Thomas S. Uldrick, Jomy M. George, Seth M. Steinberg, Priscila H. Goncalves, Kathleen M. Wyvill
Publikováno v:
Clin Cancer Res
Purpose:Kaposi sarcoma (KS) is caused by Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). KS, which develops most frequently among people with HIV, is generally treated with chemotherapy, but these drugs have acute and cu
Autor:
Linlin Yang, Wenrui Duan, Duan-Liang Shyu, Changxian Shen, Amy Webb, Min Xu, Terence M. Williams
Publikováno v:
Mol Cancer Res
Lung squamous cell carcinoma (LUSC) accounts for one of three of non–small cell lung carcinoma (NSCLC) and 30% of LUSC patients present with locally advanced, unresectable/medically inoperable disease, who are commonly treated with definitive chemo
Autor:
Dominic Edelmann, Elizabeth Alwers, Hermann Brenner, Michael Hoffmeister, Lina Jansen, Hanla A Park, Jenny Chang-Claude, Axel Benner, Martin Schneider, Federico Canzian, Petra Seibold
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 31:352-361
Background: Associations between candidate genetic variants and treatment outcomes of oxaliplatin, a drug commonly used for colorectal cancer patients, have been reported but not robustly established. This study aimed to validate previously reported
Autor:
J. Qiu, Umesh Bhanot, John T. Poirier, Yingqian Zhan, Elisa de Stanchina, Viola Allaj, Hirokazu Taniguchi, Fathema Uddin, Travis J. Hollmann, Jordana Ray-Kirton, Metamia Ciampricotti, Andrew Chow, Marina Asher, Richard Koche, Álvaro Quintanal-Villalonga, Jacklynn V. Egger, Yuan Hao, Joseph M. Chan, Shweta S Chavan, Charles M. Rudin, Michael H.A. Roehrl, Triparna Sen, Michael Offin, Irina Linkov, Nisargbhai S. Shah, P. Manoj
Publikováno v:
Cancer Res
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past several decades has been platinum-based doublet chemotherapy, with the recent addition of
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a
Autor:
Yinzhong Shang, Linlin Yan, Mingming Wu, Yong Zhu, Tao Zhu, Hui Yuan, Xiao Zhang, Zhengsheng Wu, Qianying Guo, Peter E. Lobie, Xin Ma
Publikováno v:
Cancer Research. 82:391-405
Estrogen receptor alpha (ERα) plays a vital role in the development of normal breast tissue and in breast cancer. By cross-analyzing The Cancer Genome Atlas (TCGA) database, ERα-regulated long noncoding RNA 1 (ERLC1) was identified as a long noncod
Autor:
Graham A. Colditz, Brenda M. Birmann, Irene M. Ghobrial, Timothy R. Rebbeck, Dong-Hoon Lee, Catherine R. Marinac, Bernard Rosner, Mark Bustoros
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 31:479-485
Background: Inflammation is important in multiple myeloma pathogenesis, and regular aspirin use has been shown to confer a reduced risk of multiple myeloma. The influence of aspirin on survival after multiple myeloma diagnosis is unknown. Methods: We
Autor:
Ryan C. Gimple, Guoxin Zhang, Linjie Zhao, Leo J.Y. Kim, Jia Z. Shen, Cheryl Kim, Briana C. Prager, Xujun Wang, Jean A. Bernatchez, Xiang-Dong Fu, Jeremy N. Rich, Kailin Yang, Jair L. Siqueira-Neto, Deobrat Dixit, Zhixin Qiu, Lukas Chavez, Zhe Zhu, Deguan Lv, Ye Zheng, Denise Hinz, Zhengyu Liang, Charles Spruck, Xiuxing Wang, Chunyu Jin, Qiyuan Yang, Qiulian Wu, Lihua Min, Katherine A. Jones, Zhen Dong, Shruti Bhargava
Publikováno v:
Cancer Discov
Glioblastoma (GBM) is the most lethal primary brain cancer characterized by therapeutic resistance, which is promoted by GBM stem cells (GSC). Here, we interrogated gene expression and whole-genome CRISPR/Cas9 screening in a large panel of patient-de
Autor:
Roberto Fiorelli, Chelsea Pennington-Krygier, Jing Li, Wonsuk Yoo, Xun Bao, Seongho Kim, Alanna Derogatis, Nader Sanai, Shwetal Mehta
Publikováno v:
Clinical Cancer Research. 28:289-297
Purpose: Ceritinib is an orally bioavailable, small-molecule inhibitor of anaplastic lympoma kinase (ALK), insulin-like growth factor 1 receptor (IGFR1), and focal adhesion kinase (FAK), which are highly expressed in glioblastoma and many brain metas